## Contents

**Cancer Research**  
October 15, 2013 • Volume 73 • Number 20

### BREAKING ADVANCES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6097</td>
<td>Highlights from Recent Cancer Literature</td>
</tr>
</tbody>
</table>

### REVIEWS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6099</td>
<td>RSK Isoforms in Cancer Cell Invasion and Metastasis</td>
</tr>
<tr>
<td>6106</td>
<td>The Evolution of Melanoma Resistance Reveals Therapeutic Opportunities</td>
</tr>
</tbody>
</table>

### PERSPECTIVES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6111</td>
<td>Formalizing an Integrative, Multidisciplinary Cancer Therapy Discovery Workflow</td>
</tr>
<tr>
<td>6118</td>
<td>Redox Imbalance and Biochemical Changes in Cancer</td>
</tr>
</tbody>
</table>

### MEETING REPORT

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6124</td>
<td>Twenty-fifth Annual Pezcoller Symposium: Metabolism and Tumorigenesis</td>
</tr>
</tbody>
</table>

### PRIORITY REPORT

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6128</td>
<td>A Comparative Genomic Approach for Identifying Synthetic Lethal Interactions in Human Cancer</td>
</tr>
</tbody>
</table>

### CLINICAL STUDIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6137</td>
<td>Specific Recruitment of γδ Regulatory T Cells in Human Breast Cancer</td>
</tr>
</tbody>
</table>

### INTEGRATED SYSTEMS AND TECHNOLOGIES

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6149</td>
<td>Novel Modeling of Cancer Cell Signaling Pathways Enables Systematic Drug Repositioning for Distinct Breast Cancer Metastases</td>
</tr>
</tbody>
</table>

### MICROENVIRONMENT AND IMMUNOLOGY

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>6155</td>
<td>Integrin αvβ3 and Fibronectin Upregulate Slug in Cancer Cells to Promote Clot Invasion and Metastasis</td>
</tr>
</tbody>
</table>

---

A Journal of the American Association for Cancer Research  
www.aacrjournals.org
Targeting FSTL1 Prevents Tumor Bone Metastasis and Consequent Immune Dysfunction
Chie Kudo-Saito, Takaafumi Fuwa, Kouichi Murakami, and Yutaka Kawakami

Précis: These important findings offer preclinical proof-of-concept for an attractive therapeutic target to prevent or treat bone metastasis, in part through a unique mechanism that can degrade an immune escape barrier erected by tumor cells.

MOLECULAR AND CELLULAR PATHOBIOLOGY

Carboxyl-Terminal Modulator Protein Positively Regulates Akt Phosphorylation and Acts as an Oncogenic Driver in Breast Cancer

Précis: These results address some controversy in the field by corroborating the concept that an Akt-binding molecule promotes Akt phosphorylation and functions as an oncogenic molecule in breast cancer.

GPR116, an Adhesion G-Protein-Coupled Receptor, Promotes Breast Cancer Metastasis via the Gq6p63RhoGEF-Rho GTPase Pathway
Xiaolong Tang, Rongrong Jin, Guojun Qu, Xiu Wang, Zhenxi Li, Zengjin Yuan, Chen Zhao, Stefan Siwko, Tielu Shi, Ping Wang, Jianru Xiao, Mingyao Liu, and Jian Luo

Précis: Identification of a G-protein coupled receptor that is crucial for the metastasis of breast cancer cells has implications for prognosis and targeting of advanced forms of human breast cancer.

Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
Barbara S. Paugh, Xiaoyan Zhu, Chunxu Qu, Raelene Endersby, Alexander K. Diaz, Junyuan Zhang, Dorine A. Bax, Diana Carvalho, Rui M. Reis, Araz Omar-Thomas, Alberto Broniscer, Cynthia Wetmore, Jinghui Zhang, Chris Jones, David W. Ellison, and Suzanne J. Baker

Précis: These results suggest that there is a distinct spectrum of PDGF receptor alpha mutations in adult and pediatric cancers, with implications for etiology and therapy.

THERAPEUTICS, TARGETS, AND CHEMICAL BIOLOGY

Tumor Cells Upregulate Normoxic HIF-1α in Response to Doxorubicin
Yiting Cao, Joseph M. Eble, Ejung Moon, Hong Yuan, Douglas H. Weitzel, Chelsea D. Landon, Charleen Yu-Chih Nien, Gabi Hanna, Jeremy N. Rich, James M. Provenzale, and Mark W. Dewhirst

Précis: This study suggests a means to optimize strategies for doxorubicin treatment by inhibiting the drug’s ability to upregulate HIF-1α under normoxic conditions (an unusual finding).

Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin β1/Src/Akt-Driven Bypass Signaling
Rina Kanda, Akiko Kawahara, Kosuke Watari, Yuichi Murakami, Kahori Sonoda, Masashi Maeda, Hideaki Fujita, Masayoshi Kage, Hidetaka Uramoto, Carlota Costa, Michihiro Kuwano, and Mayumi Ono

Précis: Acquired resistance to cancer cell-targeted therapies invariably poses clinical problems for resolution due to the inherent heterogeneity and plasticity of all human tumors, but combining agents that anticipate common resistance pathways may make it possible to delay relapses.

EGFR-Activating Mutations Correlate with a Fanconi Anemia–like Cellular Phenotype That Includes PARP Inhibitor Sensitivity
Heike N. Pfaffle, Meng Wang, Liliana Gheorghiu, Natalie Ferraiolo, Patricia Greninger, Kerstin Borgmann, Jeffrey Settleman, Cyril H. Benes, Leica V. Sequist, Lee Zou, and Henning Willers

Précis: These findings reveal mechanisms underlying cisplatin and PARP inhibitor sensitivity of EGFR-mutant lung cancer, potentially yielding therapeutic opportunities for further individualization of therapy in this subset of patients.

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Miguel F. Segura, Barbara Fontanals-Cirera, Avital Gaziel-Sorran, Maria V. Guirarro, Doug Hanniford, Guangtao Zhang, Pilar González-Gomez, Marta Morante, Luz Jubierre, Weiija Zhang, Farbod Darvishian, Michael Ohlmeyer, Iman Osman, Ming-Ming Zhou, and Eva Hernando

Précis: These findings strengthen a rationale for epigenetic treatment of melanomas based on pharmacologic targeting of a core transcriptional program that sustains melanoma cell identity.
NSD2 Is Recruited through Its PHD Domain to Oncogenic Gene Loci to Drive Multiple Myeloma
Zheng Huang, Haiqing Wu, Shannon Chuai, Fiona Xu, Feng Yan, Nathan Englund, Zhaofu Wang, Hailong Zhang, Ming Fang, Youzhen Wang, Justin Gu, Man Zhang, Teddy Yang, Kehao Zhao, Yanyan Yu, Jingquan Dai, Wei Yi, Shaoian Zhou, Qian Li, Jing Wu, Jun Liu, Xi Wu, Homan Chan, Chris Lu, Peter Atadja, En Li, Yan Wang, and Min Hu

Precis: These findings deepen insights into how to target a transcription factor activated in multiple myeloma by a genetic translocation, with more general implications on how to attack this molecular class of targets.

Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer

Precis: Genomic and epigenomic predictors of cancer radiosensitivity have remained frustratingly elusive, a challenge addressed here by a more highly integrative marker study than has been advanced previously.

Epithelial–Mesenchymal Transition and Tumor Suppression Are Controlled by a Reciprocal Feedback Loop between ZEB1 and Grainyhead-like-2
Benjamin Cieply, Joshua Farris, James Denvir, Heide L. Ford, and Steven M. Frisch

Precis: A feedback loop between an activator of EMT and a repressor of EMT sets up a restriction point that must be breached by an overwhelming confluence of microenvironmental factors in order for a tumor cell to undergo EMT.

Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinasases
Shirley L. Markant, Lourdes Adriania Eparza, Jesse Sun, Kelly L. Barton, Lisa M. McCooig, Gerald A. Grant, John R. Crawford, Michael L. Levy, Paul A. Northcott, David Shih, Marc Remke, Michael D. Taylor, and Robert J. Wechsler-Reya

Precis: This study identifies a critical vulnerability in some pediatric medulloblastomas that is well suited to therapeutic attack by inhibiting pivotal G2-M phase cell-cycle kinases.

Histone Acetyltransferase PCAF Is Required for Hedgehog–Gli-Dependent Transcription and Cancer Cell Proliferation
Martina Malatesta, Cornelia Steinhauser, Faizaan Mohammad, Deo P. Pandey, Massimo Squarrito, and Kristian Helin

Precis: These results define an important cofactor for a signaling pathway commonly activated in certain brain cancers, suggesting its relevance as a candidate therapeutic target.

PLA2R1 Mediates Tumor Suppression by Activating JAK2
David Vindrieux, Arnaud Augert, Christophe A. Girard, Delphine Gitenay, Helene Lallet-Daher, Clotilde Wiel, Benjamin Le Calvé, Baptiste Gras, Mylène Ferrand, Stéphanie Verbeke, Yvan de Launoit, Xavier Leroy, Alain Puisieux, Sébastien Aubert, Michael Ferrais, Michael Gelb, Hélène Simonnet, Gérard Lambeau, and David Bernard

Precis: This study offers provocative findings in suggesting that Jak2 inhibitors currently in clinical trials may exert protumorigenic activity in some contexts.

Activation of MAPK Pathways due to DUSP4 Loss Promotes Cancer Stem Cell-like Phenotypes in Basal-like Breast Cancer
Justin M. Balko, Luis J. Schwartz, Neil E. Bho, Richard Kurupi, Phillip Owens, Todd W. Miller, Henry Gómez, Rebecca S. Cook, and Carlos L. Arteaga

Precis: These findings support the clinical evaluation of MEK and JNK pathway inhibitors in treatment of aggressive triple-negative breast cancers.

Interleukin-6 Is Required for Pancreatic Cancer Progression by Promoting MAPK Signaling Activation and Oxidative Stress Resistance
Yaqing Zhang, Wei Yan, Meredith A. Collins, Filip Bednar, Sabita Rakshit, Bruce R. Zetter, Ben Z. Stanger, Ivy Chung, Andrew D. Rhim, and William R. Miller

Precis: These findings suggest that the cytokine IL-6 may be essential for progression of precursor lesions in pancreatic cancer, with therapeutic implications for how to improve treatment of this deadly disease.

CORRECTION
Correction: Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target

AC icon indicates Author Choice
For more information please visit www.aacrjournals.org

A Journal of the American Association for Cancer Research www.aacrjournals.org
ABOUT THE COVER

The prognosis and quality of life of patients with breast cancer brain metastases is generally poor and there is no effective treatment. A generally applicable computational model integrated with systems biology experiments was developed and applied to reposition existing drugs that would inhibit brain metastases. Ten repositioned drug candidates with potential brain permeability were identified. In xenograft models, sunitinib (approved for treating advanced renal cell carcinoma and gastrointestinal stromal tumors) and dasatinib (approved for treating chronic myelogenous leukemia) were repositioned to prevent metastatic outgrowth of breast cancer cells in the brain. For details, see article by Zhao and colleagues on page 6149.
Cancer Research

73 (20)


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/73/20

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.